

Receipt date: 06/08/2006

10554561 - GAU: 1647

I hereby certify that this correspondence is being filed via
EFS-Web with the United States Patent and Trademark Office
on June 8, 2006.

PATENT

Attorney Docket No.: 082368-006600US
Client Reference No.: M3-A0301Y1P-US

TOWNSEND and TOWNSEND and CREW LLP

By: /Aaron Hokamura/

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Yousuke EBINA et al.

Application No.: 10/554,561

Int'l Application No.: PCT/JP04/05412

Int'l Filing Date: April 15, 2004

For: METHODS FOR MEASURING
THE INSULIN RECEPTOR ALPHA
SUBUNIT

Confirmation No.:

Examiner:

Art Unit:

INFORMATION DISCLOSURE
STATEMENT UNDER 37 CFR §1.97 and
§1.98

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The references cited on attached form PTO/SB/08A and PTO/SB/08B are being called to the attention of the Examiner. Copies of references AC-AE and AH-AK are enclosed. Copies of references AA, AB, AF and AG are not enclosed since they were cited in the International Search Report and/or the International Preliminary Report on Patentability issued in the corresponding PCT application, and, as such, should have been provided directly by WIPO under the exchange program between the USPTO, the EPO and the JPO. A copy of the International Search Report and the International Preliminary Report on Patentability are enclosed.

References AA, AB and AG are not in the English Language. Reference AA (JP 8-103280) is categorized as an "A" document on the enclosed International Search Report. References AB (JP 2003-337131) and AG (Kikuchi *et al.*) are each cited as both "P" and "X" documents on the International Search Report. References AB and AG are also cited on the International Preliminary Report on Patentability.

It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR §1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Applicant believes that no fee is required for submission of this statement. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,

/Kevin Bastian/

Kevin Bastian
Reg. No. 34,774

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, Eighth Floor
San Francisco, California 94111-3834
Tel: 415-576-0200
Fax: 415-576-0300
KLB:ath
60783830 v1

Substitute for form 1449A&B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/554,561
				Filing Date	April 15, 2004
				First Named Inventor	Ebina, Yousuke
				Art Unit	
				Examiner Name	
Sheet	1	of	2	Attorney Docket Number	082368-006600US

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁵
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)				
/CMW/	AA	JP	8-103280	A	04-23-1996	Otsuka Pharmaceutical Co., Ltd.	** 08-103280	<input type="checkbox"/>
/CMW/	AB	JP	2003-337131	A	11-28-2003	Jenapharm GmbH & Co., KG.	**	<input type="checkbox"/>
**Reviewed English language machine translations at Patent Abstracts of Japan Website								

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
/CMW/	AC	BARON, Andre T. <i>et al.</i> ; "Soluble epidermal growth factor receptor (sEGFR/sErbB1) as a potential risk, screening, and diagnostic serum biomarker of epithelial ovarian cancer"; <u>Cancer Epidemiology, Biomarkers & Prevention</u> 12:103-113 (February 2003)			<input type="checkbox"/>
	AD	BEGUIN, Yves; "Soluble transferring receptor for the evaluation of erythropoiesis and iron status"; <u>Clinica Chimica Acta</u> 329:9-22 (2003)			<input type="checkbox"/>
	AE	FRODE, Tania Silvia <i>et al.</i> ; "Tumour necrosis factor- α , interleukin-2 soluble receptor and different inflammatory parameters in patients with rheumatoid arthritis"; <u>Mediators of Inflammation</u> 11:345-349 (2002)			<input type="checkbox"/>
	AF	KANEZAKI, Yoshiko <i>et al.</i> ; "Injection of the insulin receptor subunit increased blood glucose levels in mice"; <u>Biochem Biophys Res. Commun.</u> 309:572-577 (2003)			<input type="checkbox"/>
	AG	KIKUCHI, Kunimi <i>et al.</i> ; "Saibo seicho inshi receptor to gan idenshi sanbutsu (II) insulin receptor"; <u>Tanpakushitsu Kakusan Koso (Protein, Nucleic Acid and Enzyme)</u> 30(13):1388-1393 (1985)			<input type="checkbox"/>
	AH	SCHAEFER, Erik M. <i>et al.</i> ; "A new transgenic mouse model of chronic hyperglycemia"; <u>Diabetes</u> 43:143-153 (January 1994)			<input type="checkbox"/>
/CMW/	AI	SHIMADA, Fumio <i>et al.</i> ; "Insulin-resistant diabetes associated with partial deletion of insulin-receptor gene"; <u>The Lancet</u> 335:1179-1181 (May 19, 1990)			<input type="checkbox"/>

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A&B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/554,561
				Filing Date	April 15, 2004
				First Named Inventor	Ebina, Yousuke
				Art Unit	
Sheet	2	of	2	Examiner Name	
				Attorney Docket Number	082368-006600US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/CMW/	AJ	TAIRA, Masato <i>et al.</i> ; "Human diabetes associate with a deletion of the tyrosine kinase domain of the insulin receptor"; <u>Science</u> 245:63-66 (July 7, 1989)	<input type="checkbox"/>
/CMW/	AK	TAYLOR, Simeon I.; "Lilly lecture: Molecular mechanisms of insulin resistance: Lessons from patients with mutations in the insulin-receptor gene"; <u>Diabetes</u> 41:1473-1490 (1992)	<input type="checkbox"/>

Examiner Signature	/Cherie M. Woodward/	Date Considered	03/15/2009
-----------------------	----------------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.